MAPT and Alzheimer disease: Since a preponderance of AD subjects have low VEGF in their blood [27], TRFT has been proposed to address one of the major dysfunctions of AD and other neurologic conditions [14]—namely, the decrease in toxin cleansing/removal from the brain, thus allowing toxins to build up in the brain, aggregate into toxic oligomers within neurons (in the case of Aβ and tau), and ultimately induce deleterious effect on brain function.